Ignite Creation Date:
2025-12-25 @ 5:02 AM
Ignite Modification Date:
2026-02-25 @ 7:08 PM
Study NCT ID:
NCT02970318
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-27
First Post:
2016-11-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Sponsor:
Acerta Pharma BV
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-02-02
Start Date Type:
ACTUAL
Primary Completion Date:
2021-09-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2027-10-01
Completion Date Type:
ESTIMATED
First Submit Date:
2016-11-18
First Submit QC Date:
None
Study First Post Date:
2016-11-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-09-02
Results First Submit QC Date:
None
Results First Post Date:
2023-06-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-24
Last Update Post Date:
2025-10-27
Last Update Post Date Type:
ESTIMATED